Market capitalization | DKK95.76b |
Enterprise Value | DKK79.43b |
P/E (TTM) P/E ratio | 20.97 |
EV/FCF (TTM) EV/FCF | 12.09 |
EV/Sales (TTM) EV/Sales | 4.02 |
P/S ratio (TTM) P/S ratio | 4.85 |
P/B ratio (TTM) P/B ratio | 3.00 |
Revenue growth (TTM) Revenue growth | 16.10% |
Revenue (TTM) Revenue | DKK19.76b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
28 Analysts have issued a Genmab A/S forecast:
28 Analysts have issued a Genmab A/S forecast:
Sep '24 |
+/-
%
|
||
Revenue | 19,763 19,763 |
16%
16%
|
|
Gross Profit | 18,989 18,989 |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 6,406 6,406 |
1%
1%
|
Net Profit | 4,639 4,639 |
8%
8%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.
Head office | Denmark |
CEO | Jan Winkel |
Employees | 2,204 |
Founded | 1998 |
Website | www.genmab.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.